We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+15.95%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$41.9M
AUM Growth
-$4.22M
Cap. Flow
-$8.19M
Cap. Flow %
-19.56%
Top 10 Hldgs %
48.42%
Holding
52
New
2
Increased
17
Reduced
26
Closed
5

Top Buys

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$2.92M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$2.69M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$920K
4
ADMS
Adamas Pharmaceuticals
ADMS
+$693K
5
FBIO icon
Fortress Biotech
FBIO
+$499K

Top Sells

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$5.52M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$5.37M
3
IBB icon
iShares Biotechnology ETF
IBB
+$2.06M
4
BIIB icon
Biogen
BIIB
+$861K
5
AMGN icon
Amgen
AMGN
+$806K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$3.68M 8.78%
94,300
+82,800
+720% +$2.92M
PRQR icon
2
ProQR Therapeutics
PRQR
$327M
$2.68M 6.4%
138,461
-15,385
-10% -$164K
CLVS
3
DELISTED
Clovis Oncology, Inc.
CLVS
$2.42M 5.78%
82,430
+69,430
+534% +$2.69M
MTD icon
4
Mettler-Toledo International
MTD
$28.2B
$1.97M 4.7%
3,235
-359
-10% -$211K
ILMN icon
5
Illumina
ILMN
$34.4B
$1.82M 4.36%
5,111
-391
-7% -$125K
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$1.79M 4.26%
12,847
-887
-6% -$111K
VRTX icon
7
Vertex Pharmaceuticals
VRTX
$139B
$1.68M 4.02%
8,727
-604
-6% -$108K
LITS
8
Lite Strategy Inc
LITS
$34M
$1.55M 3.71%
18,000
-2,000
-10% -$164K
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
$1.49M 3.55%
19,288
-1,546
-7% -$114K
IONS icon
10
Ionis Pharmaceuticals
IONS
$10.4B
$1.2M 2.87%
23,293
-623
-3% -$29.3K
QGEN icon
11
Qiagen
QGEN
$9.03B
$1.2M 2.86%
29,819
-1,038
-3% -$41.5K
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$31.7B
$1.18M 2.82%
13,499
-613
-4% -$61.7K
AGIO icon
13
Agios Pharmaceuticals
AGIO
$2.05B
$1.17M 2.78%
15,102
-731
-5% -$58.8K
ACHN
14
DELISTED
Achillion Pharmaceuticals
ACHN
$1.14M 2.71%
+308,569
New +$920K
ALKS icon
15
Alkermes
ALKS
$8.2B
$1.07M 2.56%
25,242
-310
-1% -$13.5K
LOXO
16
DELISTED
Loxo Oncology, Inc
LOXO
$1.06M 2.53%
6,210
-690
-10% -$116K
KYNB
17
Kyntra Bio
KYNB
$32.4M
$1.04M 2.49%
686
-51
-7% -$78.5K
REGN icon
18
Regeneron Pharmaceuticals
REGN
$83.2B
$1.02M 2.44%
2,531
-167
-6% -$63.6K
BMRN icon
19
BioMarin Pharmaceuticals
BMRN
$12.6B
$956K 2.28%
9,854
-482
-5% -$48.1K
ADMS
20
DELISTED
Adamas Pharmaceuticals
ADMS
$891K 2.13%
44,500
+29,500
+197% +$693K
CELG
21
DELISTED
Celgene Corp
CELG
$872K 2.08%
9,747
+23
+0.2% +$2.03K
INCY icon
22
Incyte
INCY
$25.9B
$853K 2.04%
12,345
+24
+0.2% +$1.65K
NKTR icon
23
Nektar Therapeutics
NKTR
$2.55B
$720K 1.72%
787
+218
+38% +$186K
PCRX icon
24
Pacira BioSciences
PCRX
$1.03B
$553K 1.32%
11,250
-1,250
-10% -$54K
ICPT
25
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$505K 1.21%
3,998
– –
1
2 3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q3 2018 Portfolio in Review

As of Q3 2018, Opus Point Partners Management held 52 positions worth $41.9M, down 9.2% from $46.1M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Opus Point Partners Management withdrew a net $8.19M in Q3 2018, closing 5 positions and reducing 26 holdings. Its most notable exit was State Street SPDR S&P Biotech ETF, an estimated $5.52M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 72% a quarter earlier.

Against the trend, Opus Point Partners Management opened a new position in Achillion Pharmaceuticals worth $1.14M.

  • Opus Point Partners Management's largest Q3 2018 buy was Achillion Pharmaceuticals: 308,569 shares worth $1.14M.
  • Opus Point Partners Management added most to TESARO, Inc. in Q3 2018, an estimated $2.92M increase.
  • Opus Point Partners Management's biggest Q3 2018 reduction was Biogen, cutting an estimated $861K.
  • Opus Point Partners Management fully exited State Street SPDR S&P Biotech ETF in Q3 2018, selling an estimated $5.52M.
  • Opus Point Partners Management's ten largest holdings make up 48% of its $41.9M portfolio in Q3 2018.
  • Opus Point Partners Management opened 2 new positions and closed 5 in Q3 2018.
  • Opus Point Partners Management's portfolio value fell 9.2% quarter-over-quarter to $41.9M.

Based on Opus Point Partners Management's 13F filing for Q3 2018, filed 14 Nov 2018.